Who are we?
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Each day, our employees around the world work together for patients – it drives everything we do. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases.
Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm.
Our medicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through our R&D organization, we have built a sustainable pipeline of potential therapies and partner with external innovation to broaden and accelerate our work.
We work sustainably, responsibly and seek to give back. Through the Bristol-Myers Squibb Foundation, we promote health equity and strive to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.
Drugs Disributed by Bristol-Myers Squibb, Israel
Engineered Autologous T Cell Immunotherapy product. lisocabtagene maraleucel 1.1-70 x 10^6 cells/mL. Vial 1X 4.6 ml for IV inf.
For autologous use.
Tmt. consists of a sgle. dose containing a dispersion for inf. of CAR-positive viable T cells in one or more vials.
The target dose is 100 x 106 CAR-positive viable T cells (consisting of a target 1:1 ratio of CD4+ and CD8+ cell components) within a range of 44-120 x 106 CAR-positive viable T cells.
For adult pts. with large B-cell lymphoma (LBCL), incl. diffuse large B-cell lymphoma (DLBCL) not otherwise specified (incl. DLBCL arising from indolent lymphoma), high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have:
refractory dis. to first-line chemoimmunother. or relapse within 12 months of first-line chemoimmunother.; or
refractory dis. to first-line chemoimmunother. or relapse after first-line
chemoimmunother. and are not eligibale for hematopoetic stem cell transplant. (HSCT) due to comorbidities or age.
For adult pts. with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), after two or more lines of systemic ther.
C/I:Hypersens. Contraindic. of the lymphodepleting chemother. must be considered.
IgG4 Monoclonal Antibody. Nivolumab 10 mg/ml. VIALS (IV infus.).: 4ml, 10ml. 3 mg/kg
admin. as an IV infuse. over 60 min. every 2 wks. until dis. progress. or unaccept. toxicity. See lit.
Tmt. of pts. with advanced (unresect., metastatic) melanoma in adults. - As monotherapy and in combination with ipilimumab.
Tmt. of advanc. (unresect./metastat.) melanoma in adult.
In comb. with ipilimumab, is indic. for the tmt. of pts. with advanc. (unresect./metast.) melanoma.
Tmt. of pts. with metast. NSCLC with progres. on or after plat.-based chemother.
Tmt. of pts. with advance. renal cell carcin.(RCC) who have receiv. prior anti-angiog. ther.
Tmt. of pts. classic. Hodgkin lymph. (cHL) that has relapsed or progres. after autologous hematopoiet. stem cell transplant. (HSCT) & post transplant. brentuximab vedotin.
Tmt. of pts. with recur./metast. squam. cell carcin. of the head & neck (SCCHN) with dis. progres. on or after plat. based ther.
Tmt. of adut. & ped. pts. 12 yrs. & old. with microsatellite instabil.-high (MSI-H) or mismatch repair defic. (dMMR) metast. colorect. cancer (CRC) that has progres. follow. tmt. with a fluoropyrimidine, oxaliplatin, & irinotecan.
Tmt. of pts. with local. advance. or metast. urothelial carcin. who: Have dis. progres. during or follow. plat.-contain. chemother.
Have dis. progres. within 12 mnths. of neoadjuvant or adjuv. tmt. with plat. contain. chemother.
Tmt. of pts. with hepatocel. carcin. Child-Pugh A after sorafenib ther.
C/I: Hypersens.
IgG4 Monoclonal Antibody. Nivolumab 12 mg/ml, Relatlimab 4 mg/ml. 12 mg nivolumab+ 4 mg relatlimab/ml
Conc. for sol. for IV,1 X 20 ml
480 mg nivolumab and 160 mg relatlimab every 4 weeks as IV over 30 min. For adlts. and ped. pts 12 years and older weighing at least 30 kg
Tmt. of adlt and ped. pts. 12 years or older with unresect. or metast. melanoma
C/I:Hypersens
Selective Immunosuppressants. Abatacept 125 mg/ml, 250 mg. PRE-FILLED SYRINGE: 4 Syr (single dose)
125 mg SC inj. once wkly. W or w/o an
IV load. dose. Pts. transit. from IV ther.
to SC administ. 1st SC dose instead of
the next scheduled IV dose.
Reduct. signs and symp., inducing
major clinic. response, inhib. the
progress. of struct. damage, and
improve. phys. func. in adult pts. with
moderat. to severe. act. RA.
Used as monother.or concom. DMARDs
other than TNF antagonists.
VIAL (pwdr for conc. for infus.): 1x250mg. See lit.
As monotherapy for tmt. mod.-severe
active rheum. arthrit. in adults with
DMARDs other than TNF antagonists . A
reduct. in progress. joint damage and
improv. phys. funct. have been
demonstrat. In combinat. tmt. with abatacept and methotrexate. In
combinat.with methotrexate for tmt.
mod.-severe active polyarticul. juvenile
idiopathic arthrit. (JIA) in ped. pts 6 yrs of
age and older, with insuffic. response to
other DMARDs incl. at least one TNF
inhibitor. Has not been studied in child. <
6 yrs.
C/I: Should not be administered
concomitantly with TNF antagonists. Is
not recommended for use
concomitantly with other biologic
rheumatoid arthritis (RA) therapy.
Protein Kinase Inhibitor. Dasatinib 20, 50, 70, 100 mg. F.C. TABS: 60 x 20, 50, 70 mg. 30 x 100mg.
To be swallowed whole. Adults (from
18 yrs): Chronic phase CML: 100 mg dly
with/out food. Accelerat. myeloid/
lymphoid blast phase CML or Ph+ALL:
70 mg 2 x dly.
Adult, chronic, accelerat. or blast phase
CML with resistance/ intolerance to prior
therapy incl. imatinib mesilate. Adults,
Philadelphia chromosome positive (Ph+)
ALL and lymphoid blast CML with
resistance/intolerance to prior therapy.
C/I: Hypersens., pregn., lact.
Monoclonal Antibody. Ipilimumab 5 mg/ml. VIAL (conc. for sol. for I.V. infus.): 10 ml
(50 mg ipilimumb), 40 ml (200 mg
ipilimumb). 3 mg/kg admin. IV over 90
min. every 3 wks. for a total of 4 doses.
Tmt. advanc., unresect./metastat.
melanoma. As monotherapy and in
combination with nivolumab.
C/I: Hypersens.
